Takeaways From Teva's Analyst Day: 'Restoring Shareholder Value'
By Logical Assessment : Thesis Following Teva Pharmaceutical's ( TEVA ) Analyst Day , investors were met with a disappointing sell off of roughly 10% within a week, in response to downgrades issued by Leerink Swann and RBC
. Teva CEO
Jeremy Levin's words appeared to indicate a shift in strategy, ...
Read the rest of this article on Israel Stocks News and Analysis from Seeking Alpha